News & Events
Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (opens in a new tab)
SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout on track for September VOWST asset sale to provide $175M cash infusion, less approximately $20M in settlement of net obligations between the Parties, at close Transaction proceeds to fully retire debt and support advancement of…
Genetic Analysis launches consumer microbiome testing platform through Prokarimi, powered by GA-map® technology (opens in a new tab)
OSLO, NORWAY – August 8, 2024: Microbiome DX company Genetic Analysis AS (“GA”) announces the completion and launch of a consumer microbiome testing platform in partnership with Prokarimi AS (“Prokarimi”). This strategic initiative marks GA’s presence in the Nordic consumer market via its partner, offering an accessibl…
Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science (opens in a new tab)
Upon closing, Seres to receive $175M cash infusion, including an upfront payment, prepayment of a future commercial milestone payment, and an equity investment in Seres common stock, less approximately $20M in settlement of net obligations between the Parties; anticipated deal closing in the next…
Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024 (opens in a new tab)
CAMBRIDGE, Mass. , Aug. 06, 2024 (GLOBE NEWSWIRE) — Seres Therapeutics , Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 13, 2024 at 8:30 a.m. ET to discuss second quarter 2024 financial…
Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial (opens in a new tab)
Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage activity CAMBRIDGE, Mass., July 23, 2024 – Vedanta Biosciences, a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal disease…
Minutes from the Extraordinary General Meeting 17 July 2024 in Genetic Analysis AS (opens in a new tab)
The post Minutes from the Extraordinary General Meeting 17 July 2024 in Genetic Analysis AS appeared first on Genetic Analysis.…
Genetic Analysis AS: Minutes from the Extraordinary General Meeting 17 July 2024 (opens in a new tab)
Oslo, Norway, July 17, 2024 – Genetic Analysis AS (the “Company”, Ticker: GEAN) held an Extraordinary General Meeting today, July 17[th], at 09:00 hours (CET) on the Company’s premises in Ulvenveien 80, Oslo. All items on the agenda were approved as proposed. The agenda for the meeting was as follows: Opening of the me…
Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises (opens in a new tab)
OSLO, NORWAY – July 15, 2024: Microbiome DX company Genetic Analysis AS (“GA” or the “Company”) hereby announces that the direct issue which was announced in a press release on the 01.07.2024 has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret). GA announced that a direct…
Notice of Extraordinary General Meeting 2024 (opens in a new tab)
The post Notice of Extraordinary General Meeting 2024 appeared first on Genetic Analysis.…
Genetic Analysis AS: Notice of Extraordinary General Meeting 2024 (opens in a new tab)
Oslo, Norway, July 3, 2024 – Notice is hereby served that an extraordinary general meeting of Genetic Analysis AS (the “Company”) will be held on Wednesday 17 July 2024 at 09:00 hours in the Company’s premises in Ulvenveien 80, Oslo. Shareholders are encouraged to submit a proxy with voting instructions prior to the ge…
Genetic Analysis: Flagging notification (opens in a new tab)
OSLO, NORWAY – July 1, 2024: Microbiome DX company Genetic Analysis AS (“GA” or the “Company”) hereby announces that an existing shareholder, Muen Invest AS, crosses the flagging threshold as a result of the recently announced directed share issue. Muen Invest AS currently holds 2.101.794 shares, corresponding to 4,98%…
Genetic Analysis announces placement of a directed share issue of approximately NOK 4.97 million (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Genetic Analysis: Awarded important EU patent covering a companion diagnostic method for optimising IBS interventions (opens in a new tab)
OSLO, NORWAY – 13 June 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today the grant of an important patent (EP3526340) by the European Patent Office (EPO) entitled “A COMPANION DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIETARY INTERVENTIONS OR FAECA…
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science (opens in a new tab)
Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performance under a transition services agreement Future Company focus on advancement of SER-155 and other…
Genetic Analysis AS: CFO resigns to pursue other opportunities (opens in a new tab)
OSLO, NORWAY – 06 June 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that Eilert Aamodt has decided to resign as CFO to take on a new position in another company and industry. He will remain in his current role until the end of August 2024, ensuring a smooth and efficient transition …
Genetic Analysis AS: Publication of Q1 report January – March 2024 (opens in a new tab)
OSLO, NORWAY – May 29, 2024: Today, Microbiome DX company Genetic Analysis AS (“GA” or the “Company”) hereby publishes the interim report for the period January 1 – March 31, 2024. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report. Ronny H…
Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection (opens in a new tab)
VE303 is an orally administered, potential first-in-class live biotherapeutic product candidate being developed to prevent recurrence of Clostridioides difficile infection (CDI) CAMBRIDGE, MA, May 21, 2024 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies base…
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (opens in a new tab)
Continued market adoption of VOWST® with approximately 1,411 patient enrollment forms received, approximately 1,083 new patient starts, and net sales of $10.1 million during Q1 2024, and accelerated net sales in March and April SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout expected…
Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–May 6, 2024– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and…
Vedanta Biosciences Awarded $3.9 Million from CARB-X to Ready VE707 for First-in-Human Study for Prevention of Multidrug-Resistant Infections (opens in a new tab)
CAMBRIDGE, MA, April 30, 2024 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has been awarded $3.9 million in funding from the global nonprofit Combating Antibiotic-Resistant Bacteria Biopharmace…